Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma

Anti-Cancer Drugs

Volumn 23, Issue 7, 2012, Pages 745-748

  Mir, Olivier ^a   Boudou Rouquette, Pascaline ^a   Larousserie, Frédérique ^a   Blanchet, Benoit ^a   Babinet, Antoine ^a   Anract, Philippe ^a   Goldwasser, François ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

alveolar soft part sarcoma; angiogenesis inhibitors; bevacizumab; sarcoma; soft tissue sarcoma; sunitinib; vascular endothelial growth factor A

Indexed keywords

AMLODIPINE; BEVACIZUMAB; OPIATE; SUNITINIB;

AGED; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; LEG; LEG PAIN; LUNG METASTASIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEINURIA; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; TUMOR BIOPSY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LEG; LUNG; LUNG NEOPLASMS; SARCOMA, ALVEOLAR SOFT PART; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 84863565831     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283514b8c     Document Type: Article

References (20)

1. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009; 15:1096-1104.
2. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, et al. Alveolar soft part sarcoma: Clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol 2010; 17:3229-3233.
3. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, et al. Sunitinib in advanced alveolar soft part sarcoma: Evidence of a direct antitumor effect. Ann Oncol 2011; 22:1682-1690.
4. Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, et al. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther 2011; 10:861-873.
5. Gardner K, Judson I, Leahy M, Barquin E, Marotti M, Collins B, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 2009; 27:10523.
6. Kummar S, Strassberger A, Monks A, Ivy SP, Turkbey IB, Choyke PL, et al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). J Clin Oncol 2011; 29:10001.
7. Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, et al. Development and validation of an HPLC-uv-Visible method for sunitinib quantification in human plasma. Clin Chim Acta 2009; 404:134-139.
8. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J ClinOncol 2006; 24:25-35. (Pubitemid 46630490)
9. Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S, et al. Treatment of bevacizumab-Induced hypertension by amlodipine. Invest New Drugs 2010. DOI: 10.1007/s10637-10010-19549-10635.
10. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
11. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-Line bevacizumab-Based therapy in advanced nonsquamous non-Small-Cell lung cancer (SAiL, MO19390): A phase 4 study. Lancet Oncol 2011; 11:733-740.
12. Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009; 69:64-72.
13. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-Cell carcinoma: An expanded-Access trial. Lancet Oncol 2009; 10:757-763.
14. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1432-1439.
15. Tlemsani C, Mir O, Boudou-Ruoquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-vegf agents. Target Oncol 2011; 6:253-258.
16. Azizi AA, Haberler C, Czech T, Gupper A, Prayer D, Breitschopf H, et al. Vascular-Endothelial-Growth-Factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 2006; 7:521-523. (Pubitemid 43779166)
17. Conde N, Cruz O, Albert A, Mora J. Antiangiogenic treatment as a preoperative management of alveolar soft-Part sarcoma. Pediatr Blood Cancer 2011; 57:1071-1073.
18. Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, et al. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. J Pediatr Hematol Oncol 2009; 31:561-570.
19. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10:2298-2308.
20. Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): A report from the Juvenile RCC Network. Ann Oncol 2010; 21:1834-1838.